New drug combo tested for Tough-to-Treat sarcomas
NCT ID NCT07027423
Summary
This early-stage trial aims to find a safe dose of a new drug called BOLD-100 when given with standard chemotherapy (doxorubicin) for advanced soft tissue sarcoma. It will enroll about 32 adults who haven't had prior treatment for their advanced disease. The main goal is to check how well patients tolerate the combination and to monitor side effects and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UHN- Princess Margaret Cancer Center
Toronto, Ontario, M5G 1Z5, Canada
Conditions
Explore the condition pages connected to this study.